Is SRPT a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Elevidys franchise durability, with 2026 revenue guidance at ~$1.2B-$1.4B. The bear case rests on the defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. Analysts covering it are spread from $5.00 to $38.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $5.00, -67.3% from the $15.31 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Elevidys franchise durability. Elevidys was the largest growth driver before the safety events, and its trajectory now hinges on a narrower label focused on ambulatory patients plus prescriber and payer confidence. The most optimistic analyst target on SRPT is $38.00, +148.2% from the $15.31 price. That figure is only reachable if this thesis works close to its best case.

The defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. Regulatory posture toward Elevidys and future gene therapies is uncertain and could further narrow labels or restrict use. Sarepta is heavily concentrated in a single disease (DMD), so a franchise setback has outsized impact. Competition is intensifying from Dyne Therapeutics, Avidity Biosciences, REGENXBIO, Pfizer, and Solid Biosciences, several of which could reach the market in 2026-2027. As a biotech that has cut a third of its staff amid falling revenue, execution, litigation exposure, and financing risk all remain elevated. The most pessimistic published target is $5.00, -67.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Sarepta Therapeutics is a biotechnology company focused almost entirely on Duchenne muscular dystrophy (DMD), a fatal muscle-wasting genetic disease.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Elevidys franchise durability) stalling in the reported numbers rather than in the narrative, the risk above (the defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Sarepta is a rare-disease biotech focused on Duchenne muscular dystrophy. It sells Elevidys, a gene therapy, and a set of older RNA-based exon-skipping drugs (Exondys 51, Vyondys 53, Amondys 45) that treat specific genetic subsets of DMD patients.

Elevidys (delandistrogene moxeparvovec) is Sarepta's gene therapy for DMD, delivered using the AAVrh74 viral vector. It was the company's largest growth product before 2025-2026 safety events narrowed its label and disrupted distribution.

In 2025 Sarepta reported multiple patient deaths from acute liver failure associated with its AAVrh74 gene-therapy vector, including cases tied to Elevidys and a separate trial. The events triggered a boxed warning, loss of FDA platform designation, a shipment halt, and a clinical hold.